Fig. 5From: Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference studyPercentage of respondents on each side of the baseline for each risk. A Switch From Oral to IV, n = 92. B Switch From IV to Oral, n = 58. AE = adverse event; HFSR = hand-foot skin reaction; IV = intravenousBack to article page